title: Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study.
abstract: OBJECTIVE
  To assess delayed epithelialization and corneal haze related to nepafenac ophthalmic suspension 0.1% (Nevanac) use after photorefractive keratectomy (PRK).
  
  
  METHODS
  Private practice, Beverly Hills, California, USA.
  
  
  METHODS
  This retrospective comparative chart review comprised 69 eyes (44 patients) that were divided into 2 treatment groups that were not statistically significantly different in age or preoperative spherical equivalent. The nepafenac group consisted of 34 eyes (22 patients) that received nepafenac 0.1%, moxifloxacin, and fluorometholone postoperatively. The non-nepafenac group included 35 eyes (22 patients) that received moxifloxacin and fluorometholone only. Patients were seen between 1 day and 5 days postoperatively for evaluation of epithelial healing and haze formation. Delayed epithelialization was defined as healing after day 5. All patients were followed for haze formation for a minimum of 3 months.
  
  
  RESULTS
  Statistical analysis showed no difference between the nepafenac and non-nepafenac groups in delayed epithelialization (P = .61, chi-square test). Neither group had significant corneal haze.
  
  
  CONCLUSIONS
  Nepafenac did not appear to delay corneal epithelial healing or contribute to haze formation after PRK.
authors: Boxer Wachler Vision Institute, 465 North Roxbury Drive, Beverly Hills, CA 90210, USA.
authors: Shahrokh
authors: S
authors: Jalali
authors: Leonard H
authors: LH
authors: Yuen
authors: Brian S
authors: BS
authors: Boxer Wachler
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D044482:Benzeneacetamides / Q000008:administration & dosage*; D003318:Corneal Opacity / Q000209:etiology* / Q000503:physiopathology; D019573:Epithelium, Corneal / Q000187:drug effects*; D005260:Female; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D009216:Myopia / Q000601:surgery; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D010648:Phenylacetates / Q000008:administration & dosage*; D018903:Photorefractive Keratectomy; D011355:Prodrugs / Q000008:administration & dosage*; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D044482:Benzeneacetamides; D009883:Ophthalmic Solutions; D010648:Phenylacetates; D011355:Prodrugs; C414203:nepafenac